European Union & Sanofi

European Union: Venglustat is also under regulatory review in the European Union, indicating potential future market expansion for Sanofi.

Sanofi: Sanofi has received priority review for its drug venglustat, which could significantly expand its portfolio in lysosomal storage diseases and provide a new revenue stream if approved.

European Union: EU patent for Aqueol is in final approval stages, which could open a major market for Pulse.

Sanofi: Already a customer of Pulse's manufacturing, the approval may strengthen their supply relationship.

European Union: The EU is reviewing mFLUSIVA, which could expand Moderna's market access.

Sanofi: Sanofi's high-dose flu vaccine served as a comparator in trials; the new mRNA vaccine may compete with its products.

European Union: The EU approved Awiqli, supporting its international availability.

Sanofi: Sanofi's Lantus faces new competition from Awiqli, which offers less frequent dosing and lower cost per unit.

European Union: The EU is one of the regions where QDENGA has received regulatory approval, indicating its acceptance in developed markets.

Sanofi: Sanofi's dengue vaccine Dengvaxia is not approved in India and is only recommended for those with prior infection, contrasting with QDENGA's broader indication.

European Union: Regulatory jurisdiction where EMA PRIME designation and Orphan Drug designation were granted.

Sanofi: Mentioned as a collaborator with Innate, not directly involved in this partnership.

Sanofi: Sanofi, in collaboration with Regeneron Pharmaceuticals, developed Dupixent and received International — European Commission approval for its use in treating chronic spontaneous urticaria in young children, which is expected to boost its market position and revenue.